Noxopharm Ltd
Noxopharm Limited, a biotech company, engages in the discovering and developing treatments for cancer and inflammation, and mRNA vaccines in Australia. It develops Sofra, a platform that focuses on the development of immunomodulators for mRNA vaccines and mRNA therapeutics, as well as for the treatment of autoimmune diseases; and Chroma technology platform to develop CRO-67 dual-cell therapy drug… Read more
Noxopharm Ltd (NOX) - Total Liabilities
Latest total liabilities as of June 2025: AU$3.89 Million AUD
Based on the latest financial reports, Noxopharm Ltd (NOX) has total liabilities worth AU$3.89 Million AUD as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Noxopharm Ltd - Total Liabilities Trend (2016–2025)
This chart illustrates how Noxopharm Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Noxopharm Ltd Competitors by Total Liabilities
The table below lists competitors of Noxopharm Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Ackerstein Group Ltd
TA:ACKR
|
Israel | ILA697.10 Million |
|
Reborn Coffee Inc
NASDAQ:REBN
|
USA | $9.62 Million |
|
PT Hatten Bali Tbk
JK:WINE
|
Indonesia | Rp133.10 Billion |
|
Scorpion Minerals Ltd
AU:SCN
|
Australia | AU$1.33 Million |
|
Kalamazoo Resources Limited
PINK:KAMRF
|
USA | $3.61 Million |
|
New York City REIT Inc
NYSE:NYC
|
USA | $376.70 Million |
|
Sahathai Printing & Packaging PCL
BK:STP
|
Thailand | ฿182.75 Million |
Liability Composition Analysis (2016–2025)
This chart breaks down Noxopharm Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.18 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 0.40 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 5.64 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.85 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Noxopharm Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Noxopharm Ltd (2016–2025)
The table below shows the annual total liabilities of Noxopharm Ltd from 2016 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-06-30 | AU$3.89 Million | +201.99% |
| 2024-06-30 | AU$1.29 Million | +22.12% |
| 2023-06-30 | AU$1.06 Million | -57.38% |
| 2022-06-30 | AU$2.48 Million | -65.02% |
| 2021-06-30 | AU$7.08 Million | -1.63% |
| 2020-06-30 | AU$7.19 Million | +25.10% |
| 2019-06-30 | AU$5.75 Million | +30.66% |
| 2018-06-30 | AU$4.40 Million | +1119.07% |
| 2017-06-30 | AU$361.04K | +37.95% |
| 2016-06-30 | AU$261.72K | -- |